The 22 most recent market catalysts affecting $IOVA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 65
Citizens Maintains Iovance Biotherapeutics at Market Outperform and Raises Price Target
Citizens, a financial institution, has maintained its 'Market Outperform' rating on Iovance Biotherapeutics and significantly raised its price target from $8 to $12. This 50% incre…
Oct 13, 2026
Corporate Catalyst
Bullish
Impact 60
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Iovance Biotherapeutics and raised the price target from $15 to $18. This action signals increased confidence fro…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 65
Baird Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $11
Baird analyst Colleen Kusy maintained a 'Neutral' rating on Iovance Biotherapeutics (IOVA) but raised the price target from $6 to $11. This move indicates that while the analyst do…
Oct 6, 2026
Corporate Catalyst
Neutral
Impact 85
Transcript: Iovance Biotherapeutics Q2 2026 Earnings Conference Call
Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3 million, significantly surpassing guidance, driven by strong AMTAGVI demand. This indicates successful commercializ…
Sep 30, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $18
Wells Fargo analyst Yanan Zhu maintained an 'Overweight' rating on Iovance Biotherapeutics (IOVA) and raised the price target from $14 to $18. This action signals increased confide…
Sep 30, 2026
Corporate Catalyst
Bearish
Impact 75
Iovance Biotherapeutics Stock Pauses After Hitting New 52-Week High: What's Going On?
Iovance Biotherapeutics (IOVA) announced a significant increase in its 2026 revenue guidance, raising the midpoint by $55 million to $410-$420 million. This upward revision is dire…
Sep 29, 2026
Corporate Catalyst
Neutral
Impact 85
Iovance Biotherapeutics’ Amtagvi Demand Drives 2026 Revenue Guidance Bump, Stock Soars
Iovance Biotherapeutics (IOVA) announced a significant increase in its full-year 2026 revenue guidance, raising the midpoint by $55 million to $410-$420 million. This upward revisi…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Joseph Pantginis maintained a 'Buy' rating on Iovance Biotherapeutics (IOVA) and raised the price target from $9 to $20. This significant increase in th…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 85
Iovance Biotherapeutics shares are trading higher after the company raised its FY26 revenue guidance.
This headline is a significant corporate catalyst for Iovance Biotherapeutics. Raising revenue guidance for a future fiscal year (FY26) demonstrates management's increased confiden…
Sep 29, 2026
Corporate Catalyst
Bullish
Impact 85
Iovance Raises FY2026 Total Revenue Guidance From $350M-$370M To $410M-$420M
This headline is a significant corporate catalyst for Iovance Biotherapeutics (IOVA). The substantial increase in FY2026 revenue guidance, from $350M-$370M to $410M-$420M, indicate…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target
Goldman Sachs analyst Andrea Newkirk has reinstated a 'Buy' rating on Iovance Biotherapeutics (IOVA) and announced a $15 price target. This is a significant positive development fo…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 65
Iovance Biotherapeutics shares are trading higher after Barclays raised its price target on the stock from $13 to $15.
This headline indicates a positive corporate catalyst for Iovance Biotherapeutics (IOVA). An analyst upgrade, particularly a price target increase, signals improved sentiment and p…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15
Barclays analyst Etzer Darout maintained an 'Overweight' rating on Iovance Biotherapeutics (IOVA) and raised the price target from $13 to $15. This action signals increased confide…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 65
Iovance Biotherapeutics shares are trading higher after UBS maintained its Neutral rating on the stock and raised its price target from $4 to $7.
The headline indicates a positive sentiment shift for Iovance Biotherapeutics (IOVA) due to UBS raising its price target by 75%, from $4 to $7. While the rating remains 'Neutral,' …
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 65
Why Iovance Biotherapeutics Stock Hit 52-Week High
Iovance Biotherapeutics (IOVA) stock experienced a significant surge to a 52-week high, primarily due to positive breakthrough data from Moderna and Merck's individualized cancer t…
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Iovance Biotherapeutics, Raises Price Target to $11
Mizuho analyst Mara Goldstein maintained an 'Outperform' rating on Iovance Biotherapeutics and raised the price target from $10 to $11. This analyst upgrade signals increased confi…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $13
This filing discloses that Barclays analyst Etzer Darout has maintained an 'Overweight' rating on Iovance Biotherapeutics (IOVA) and raised the price target from $11 to $13. This i…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $8
Citizens analyst Reni J. Benjamin maintained a 'Market Outperform' rating on Iovance Biotherapeutics and raised the price target from $5 to $8. This indicates a strengthened convic…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Thursday's Intraday Session
The filing details the intraday performance of 12 healthcare stocks, with 6 experiencing significant gains and 6 experiencing significant losses. The primary catalyst for many of t…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 85
Iovance Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.
The better-than-expected Q2 financial results for Iovance Biotherapeutics (IOVA) are a significant positive catalyst, directly impacting the company's stock price. This indicates s…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M Estimate
This headline indicates a positive corporate catalyst for Iovance Biotherapeutics (IOVA). Beating both EPS and sales estimates suggests that the company is executing well, potentia…
Jul 21, 2026
Market Technicals
Neutral
Impact 65
10 Health Care Stocks With Whale Alerts In Today’s Session
The filing highlights 'whale' options activity across ten healthcare stocks, indicating large institutional or high-net-worth investor movements. This type of activity is often see…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.